MannKind Corporation · 1 day ago
Communications Internship
MannKind Corporation is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. They are seeking a highly motivated Communications Intern to support their Corporate Affairs team, contributing to effective internal and external communication efforts.
BiotechnologyHealth CarePharmaceutical
Responsibilities
Contribute to creating clear, engaging content for a variety of internal and external communication channels
Assist with maintaining and enhancing the organization’s online presence
Help with initiatives that keep employees informed and connected
Track relevant news and industry updates to support communication, analysis, and reporting
Provide support for planning and communication around company events
Work closely with multiple departments to gather information and support integrated communications campaigns
Qualification
Required
Currently pursuing a bachelor's degree in Communications, Public Relations, or a related field
Commit to working 40 hours per week for the full 8-12 weeks without vacation weeks
A reliable commute or the intention to find temporary housing before starting the internship is required
At this time, we are only able to consider candidates who do not require visa sponsorship, including those with a student visa
Preferred
Preferably within 1-2 years of graduation
Strong written and verbal communication skills
Familiarity with social media platforms and content creation tools; Experience with graphic design and Canva is a plus
Detail-oriented with the ability to manage multiple tasks and deadlines
Proficiency in Microsoft Office Suite
Self-motivated and demonstrated learning agility
You take the initiative to identify opportunities for improvement and act on them without needing constant direction
You are open to constructive criticism and use it to improve performance and grow professionally
Company
MannKind Corporation
MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions.
Funding
Current Stage
Public CompanyTotal Funding
$475MKey Investors
Blackstone GroupDeerfield Capital Management
2025-08-06Post Ipo Debt· $75M
2021-03-02Post Ipo Debt· $200M
2018-12-01Post Ipo Equity· $40M
Recent News
2026-01-15
2026-01-09
GlobeNewswire
2025-12-24
Company data provided by crunchbase